ARTICLE | Company News
Seattle Genetics, Eos in antibody deal
June 5, 2001 7:00 AM UTC
The companies will develop monoclonal antibodies linked to toxic payloads to target and kill cancer cells. The collaboration combines SGEN's technology for linking cytotoxic compounds to antibodies wi...